Women face prescription delays as off-label testosterone use rises
仅事实

Women face prescription delays as off-label testosterone use rises

摘要

Off-label testosterone prescriptions for menopausal symptoms have increased sharply, but many women encounter pharmacy rejections, dosing challenges and limited insurance coverage.

Off-label use of testosterone to treat menopause-related symptoms is growing, yet many women report difficulties obtaining the medication. The hormone is not approved for female use in the United States, and medical guidelines currently endorse it only for hypoactive sexual desire disorder in menopausal women.

Data from healthcare analytics firm Truveta, analyzed by Reuters, show that prescriptions for women rose 146% between January 2023 and July 2026, nearly tripling in that period. The FDA plans a public workshop to review the evidence for testosterone in menopausal women, while an agency spokesperson noted that off-label applications have not been evaluated for safety, efficacy or dosing.

Clinicians often have to split male-dosage products to achieve the lower doses women need, a practice that has drawn scrutiny from some pharmacies. A Washington, D.C., nurse practitioner said Amazon Pharmacy rejected an off-label testosterone prescription, citing a new policy, and the company indicated it does not dispense formulations that require patients to modify doses. Amazon directs such patients to compounding pharmacies, which can charge about $100 for a three-month supply compared with roughly $30 for a discounted commercial product.

Insurance coverage for testosterone in women is uncommon. A nurse practitioner who runs a sexual-wellness practice reported that more than one-third of her 80 patients experienced prescription problems at major chains such as CVS and Walgreens. One patient described spending weeks trying to apply a GoodRx discount and losing significant time in the process.

Pharmacists suggest that concerns over dosing accuracy, medication stability and controlled-substance record-keeping may drive pharmacy refusals. Over 30 clinical trials are investigating testosterone’s safety and efficacy for various female health conditions, and several companies are developing formulations aimed at reducing risks such as breast-cancer incidence.

Experts say an FDA-approved testosterone product specifically dosed for women would simplify prescribing and improve patient confidence.

来源

CNN

继续阅读——免费

创建免费账户以关注新闻。无需银行卡。